AQST logo

AQST
Aquestive Therapeutics Inc

12,571
Mkt Cap
$530.65M
Volume
515,044.00
52W High
$7.55
52W Low
$2.22
PE Ratio
-7.01
AQST Fundamentals
Price
$4.16
Prev Close
$4.23
Open
$4.26
50D MA
$4.15
Beta
1.37
Avg. Volume
1.12M
EPS (Annual)
-$0.7836
P/B
-15.44
Rev/Employee
$303,027.21
$701.02
Loading...
Loading...
News
all
press releases
Aquestive Therapeutics Q1 Earnings Call Highlights
Aquestive Therapeutics Q1 Earnings Call Highlights...
News Placeholder
More News
News Placeholder
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
News Placeholder
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +50.00% and +33.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates
CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -0.82% and +42.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know
Journey Medical (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Brokerages
Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has been assigned an average rating of "Buy" from the eight research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a...
News Placeholder
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST) and reminds investors of...
News Placeholder
Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Monday
Aquestive Therapeutics (NASDAQ:AQST) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-aquestive-therapeutics-inc-stock...
News Placeholder
Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available